The present invention relates to the treatment of cancer. In particular, the invention relates to the therapeutic use of alpha-2 adrenergic receptor agonists for the treatment of cancer. More particularly, apraclonidine, clonidine, guanfacine and guanabenz, which are alpha-2 adrenergic receptor agonists, are all capable of efficiently reducing the growth of solid tumors. The effect is immune-mediated and is abolished in the presence of an alpha-2 antagonist or in mice that are knockout for the alpha-2 adrenergic receptor.

The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. In certain embodiments, the programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, and volume of gastric fluid. The programmable osmotic-controlled oral compositions of the disclosure comprise a multilayer core comprising a drug for controlled release, wherein the core is coated with a semipermeable membrane comprising an orifice and, optionally, an immediate release coating, comprising a drug for immediate release, over the semipermeable membrane. The multilayered core comprises a pull layer containing the drug and a push layer. The pull layer comprises at least two layers: a placebo layer for providing a desired lag time for the drug release; and an active layer containing the drug and providing a delayed controlled release of the drug. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm, e.g., that matches the human circadian rhythm of a condition's symptoms and/or of the individual being treated in the application of the therapy to optimize therapeutic outcome and minimize side effects.

The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. In certain embodiments, the programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, and volume of gastric fluid. The programmable osmotic-controlled oral compositions of the disclosure comprise a multilayer core comprising a drug for controlled release, wherein the core is coated with a semipermeable membrane comprising an orifice and, optionally, an immediate release coating, comprising a drug for immediate release, over the semipermeable membrane. The multilayered core comprises a pull layer containing the drug and a push layer. The pull layer comprises at least two layers: a placebo layer for providing a desired lag time for the drug release; and an active layer containing the drug and providing a delayed controlled release of the drug. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm, e.g., that matches the human circadian rhythm of a condition's symptoms and/or of the individual being treated in the application of the therapy to optimize therapeutic outcome and minimize side effects.

Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine in a drug depot at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate drug depot formulations are provided within biodegradable polymers, this pain relief can be continued for at least fourteen days.

Disclosed herein is a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling. The formulation comprises ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base for topical application for relief of neuropathy symptoms. Disclosed herein is a method of making a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling, the formulation comprising ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base suitable for topical application. Disclosed herein is a method of using a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling, the formulation comprising ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base for topical application to relieve symptoms of neuropathy.

Disclosed herein is a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling. The formulation comprises ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base for topical application for relief of neuropathy symptoms. Disclosed herein is a method of making a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling, the formulation comprising ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base suitable for topical application. Disclosed herein is a method of using a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling, the formulation comprising ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base for topical application to relieve symptoms of neuropathy.

Disclosed herein is a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling. The formulation comprises ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base for topical application for relief of neuropathy symptoms. Disclosed herein is a method of making a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling, the formulation comprising ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base suitable for topical application. Disclosed herein is a method of using a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling, the formulation comprising ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base for topical application to relieve symptoms of neuropathy.

The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.

The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.

It is already known that 1-(benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable acid addition salt thereof exhibits an excellent effect as an antidepressant, a psychotropic drug, an antiparkinsonian drug, and an anti-Alzheimer's disease drug. However, it has not been known at all that the compound is effective for the prevention or therapy of attention-deficit/hyperactivity disorder (ADHD). The present invention has newly found that 1-(benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable acid addition salt thereof is effective for the prevention or therapy of ADHD, and has been accomplished.